|
|
|
|
|
|
|
26.05.26 - 05:45
|
CN MOC Holds Roundtable with Foreign-funded Pharmas (AAStocks)
|
|
|
Ling Ji, Vice Minister of Commerce and Deputy China International Trade Representative, chaired a roundtable meeting with foreign-funded pharmaceutical enterprises last Friday (22nd). Representatives from more than 50 foreign companies attended the meeting, including Sanofi (SNY.US), Novartis AG (NVS.US), Merck & Company, In......
|
|
|
22.05.26 - 11:00
|
Swiss Generics Giant Sandoz Urges EU to Probe Alleged Dumping by China (AAStocks)
|
|
|
According to the Financial Times, Sandoz, the worlds largest generics drugmaker spun off from Novartis and headquartered in Switzerland, has called on the European Commission to investigate imports from China of a key ingredient used in a common antibiotic, alleging unfair state subsidies.Citing a complaint filed in March this y......
|
|
|
|
|
|
|
|
|
19.05.26 - 14:33
|
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer (Business Wire)
|
|
|
Dr. Angelov brings extensive industry experience across multiple therapeutic areasSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026.
"We are pleased to welcome Dr. Angelov to the Vistagen team,” said President and Chief Executive Officer of Vistagen, Shawn Singh. “His two decades of leadership across clinical development and medical affairs, including roles at Karuna, Neurocrine, Novartis, and Teva, will be instrumental as we work to improve suboptimal standards of care in our targeted therapeutic areas.”
Dr. Angelov most recently served as CMO at Theranica, a neuromodulation therapeutics company. Previously, Dr. Angelov served as Managing Director at ANG Holding, a...
|
|
|
|
|
|
|
|
|
15.05.26 - 08:00
|
Der grosse Pharma-Meltdown (Inside Paradeplatz)
|
|
|
Japan-Takeda radiert 280 Jobs in Zürich-Opfikon aus, australische CSL Behring vernichtet 200 Stellen in Bern, Novartis 500. Black Hour.
Die Schweiz, das Pharma-Paradies. Und jetzt das. 280 Jobs gehen im Norden des Wirtschaftsmotors Zürich verloren. Das Streichkonzert von Takeda aus Japan, einem globalen Pharma-Riesen, trifft die Schweiz mit Wucht. Das berichtete die NZZ. Gleiches im Berner Vorort Wankdorf, wo […]...
|
|
|
|
|
12.05.26 - 14:25
|
Novartis Aktie: Entscheidende Readouts voraus (Aktiencheck)
|
|
|
Wien (www.aktiencheck.de) - Novartis-Aktienanalyse der Raiffeisen Bank International AG (RBI):
Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), nimmt in einer aktuellen Aktienanalyse die Aktie der Novartis AG (ISIN: CH0012005267, WKN: 904278, Ticker-Symbol: NOT, SIX SWISS-Symbol: NOVN) unter die Lupe. [mehr]...
|
|
|
10.05.26 - 22:00
|
Novartis seeks to deepen India innovation play (Times of India)
|
|
|
Swiss pharma major Novartis is sharpening its strategy in India as a pure-play innovator across core therapy segments, including cardiovascular, oncology, and immunology. The company is moving further up the value chain in India, with early scientific discovery and Phase I studies beginning to take shape....
|
|
|
08.05.26 - 12:24
|
Construction begins on Novartis′ RLT centre in Texas, US (PBR)
|
|
|
The location will serve as Novartis' first RLT manufacturing site in Texas and is the company's fifth such site in the country, increasing supply chain reach for the
The post Construction begins on Novartis' RLT centre in Texas, US appeared first on Pharmaceutical Business review....
|
|
|
|
|
07.05.26 - 15:06
|
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities (GlobeNewswire EN)
|
|
|
East Hanover, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest milestone in its broader $23 billion investment in US manufacturing and research. The start of construction on the company's first Texas‑based manufacturing facility brings US RLT production closer to patients across the southern US, becoming the fifth RLT site nationwide.“Radioligand therapy is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale,” said Vas Narasimhan, CEO of Novartis. “Breaking ground in Denton further strengthens our US supply chain and helps ensure patients can receive these highly personalized treatments when and where they need them.”This expansion reinforces Novartis' leadership as the first company to deliver RLT at scale, building the network capacity needed as these therapies extend into earlier stages of ...
|
|
|
05.05.26 - 17:51
|
Aktien Schweiz etwas fester - Nestle und Novartis bremsen (Dow Jones)
|
|
|
DOW JONES--Die schweizerische Aktienmarkt ist am Dienstag den europäischen Pendants hinterhergehinkt. Vor allem Abschläge der Schwergewichte bremsten die eidgenössische Börse aus. Die Risikoneigung habe trotz des Säbelrasselns im Nahen Osten zugenommen, ......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
